BioStem Technologies Reports Q1 2026 Revenue Drop Amid Strategic Shift to Hospital Market

BioStem Technologies, Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, reported financial results for the first quarter ended March 31, 2026, revealing a sharp decline in net revenue to $6.1 million from $16.0 million in the same period last year. The drop reflects the company’s strategic repositioning following its acquisition of surgical and wound care assets from BioTissue, with a renewed emphasis on the hospital market.

According to the company’s press release, hospital revenue accounted for approximately 87% of total revenue, or $5.4 million, in the first quarter, while physician office revenue contributed $0.8 million. CEO Jason Matuszewski stated that the quarter marked the beginning of a strategic transformation, positioning BioStem as a fully integrated, hospital-focused commercial organization. The company expanded its direct sales force to 35 representatives, up from 18 at the close of the BioTissue acquisition, and reassigned all group purchasing organization (GPO) contracts to support this shift.

Gross profit for the quarter was $3.8 million, representing a gross margin of 61%, down from 95% in the first quarter of 2025. The decline was attributed to the mix shift toward Neox® and Clarix® products, which are subject to a cost-plus markup under the current manufacturing supply agreement. The company expects gross margin to improve significantly upon completion of a planned manufacturing technology transfer in 2027.

Operating expenses totaled $12.6 million, compared to $9.9 million in the year-ago quarter, driven by the addition of the acquired workforce and expenses related to the BioTissue transaction and the uplist process. GAAP net loss was $8.8 million, or $0.52 per share, versus net income of $3.9 million, or $0.23 per share, in the first quarter of 2025. Adjusted EBITDA was negative $5.7 million, compared to positive $7.8 million a year earlier.

BioStem also retired outstanding debt with GMA, resolving two promissory notes with an aggregate principal amount of $3 million and accrued interest of $2.3 million. As of March 31, 2026, cash and cash equivalents stood at $13.7 million, down from $29.5 million at the end of the fourth quarter of 2025.

The company issued audited financial statements for 2024 and 2025 during the quarter and continues to progress toward its planned Nasdaq uplisting. BioStem expects full-year 2026 revenue to be in the range of $25 million to $29 million, with sequential growth in the hospital business anticipated in the second half of the year as integration of the BioTissue assets continues.

For more details, the company’s newsroom is available at https://tinyurl.com/bsemnewsroom. A conference call to discuss the results was held on May 14, 2026, with a webcast accessible at https://events.q4inc.com/attendee/844730655.

This news story relied on content distributed by PRISM Mediawire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is BioStem Technologies Reports Q1 2026 Revenue Drop Amid Strategic Shift to Hospital Market.

The post BioStem Technologies Reports Q1 2026 Revenue Drop Amid Strategic Shift to Hospital Market appeared first on citybuzz.